Novo Nordisk shrugs off Brexit, unveils $144M plan for a diabetes research center at Oxford
Brexit may have raised concerns about the future of academic research in the UK, but it didn’t stop Novo Nordisk from pushing ahead with plans to establish a new center for early-stage diabetes drug research at the University of Oxford. A leader in diabetes research, Novo has committed $144 million to back the research center, with plans to bring together 100 investigators for the work.
The big idea here, similar to other campus-based research ventures, is to bring together its dedicated research teams with Oxford investigators and fund new collaborations. They’re bringing in James Johnson, an expert in the field, from the University of British Columbia to run the show.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
